FDA approves Tecvayli for advanced multiple myeloma healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.
Menin inhibitors for patients with AML have been one of many improvements within the blood cancer space this year, Lee Greenberger of the Leukemia and Lymphoma Society told CURE®.